Income Taxes	9 Months Ended
Jan. 31, 2025
Income Tax Disclosure [Abstract]
Income Taxes	. Income Taxes Income tax benefit of $108,000 and income tax expense of $1,000,000 were recorded for the three and nine months ended January 31, 2025, respectively. Income tax expense of $982,000 and $3,894,000 were recorded for the three and nine months ended January 31, 2024, respectively. The effective tax rate was (8.5)% and 13.1% for the three and nine months ended January 31, 2025, respectively. The effective tax rate for the current three and nine months periods reflects the impact of foreign operations which are taxed at different rates than the U.S. tax rate of 21%, combined with expected current year tax expense for the Company's domestic operations. In addition, the income tax expense recorded for the nine months ended January 31, 2025 was favorably impacted by a discrete tax benefit of $421,000 resulting from the issuance of stock through the vesting of restricted stock units and the exercise of stock options during the first quarter. The effective tax rate was 27.9% and 33.1% for the three and nine months ended January 31, 2024, respectively. The prior year effective tax rate was influenced by foreign operations which are taxed at different rates than the U.S. tax rate of 21%, combined with expected tax expense for the Company's domestic operations and estimated increases in the domestic valuation allowance required for the corresponding period. In addition, income tax expense for the nine months ended January 31, 2024 was unfavorably impacted by additional foreign tax expense of $387,000 related to India tax matters. This one-time expense was related to management's decision to discontinue management fees, citing challenges associated with the Indian tax authority and cost benefit analysis. In August 2019, the Company revoked its indefinite reinvestment of foreign unremitted earnings position in compliance with ASC 740 "Income Taxes" and terminated its indefinite reinvestment of unremitted earnings assertion for the Singapore and Kewaunee Labway India Pvt. Ltd. international subsidiaries. The Company has a deferred tax liability of $1,431,000 and $1,572,000 for the withholding tax related to Kewaunee Labway India Pvt. Ltd. as of January 31, 2025 and April 30, 2024, respectively.

Income Taxes

9 Months Ended

Jan. 31, 2025

. Income Taxes

Income tax benefit of $108,000 and income tax expense of $1,000,000 were recorded for the three and nine months ended January 31, 2025, respectively. Income tax expense of $982,000 and $3,894,000 were recorded for the three and nine months ended January 31, 2024, respectively. The effective tax rate was (8.5)% and 13.1% for the three and nine months ended January 31, 2025, respectively. The effective tax rate for the current three and nine months periods reflects the impact of foreign operations which are taxed at different rates than the U.S. tax rate of 21%, combined with expected current year tax expense for the Company's domestic operations. In addition, the income tax expense recorded for the nine months ended January 31, 2025 was favorably impacted by a discrete tax benefit of $421,000 resulting from the issuance of stock through the vesting of restricted stock units and the exercise of stock options during the first quarter. The effective tax rate was 27.9% and 33.1% for the three and nine months ended January 31, 2024, respectively. The prior year effective tax rate was influenced by foreign operations which are taxed at different rates than the U.S. tax rate of 21%, combined with expected tax expense for the Company's domestic operations and estimated increases in the domestic valuation allowance required for the corresponding period. In addition, income tax expense for the nine months ended January 31, 2024 was unfavorably impacted by additional foreign tax expense of $387,000 related to India tax matters. This one-time expense was related to management's decision to discontinue management fees, citing challenges associated with the Indian tax authority and cost benefit analysis.

In August 2019, the Company revoked its indefinite reinvestment of foreign unremitted earnings position in compliance with ASC 740 "Income Taxes" and terminated its indefinite reinvestment of unremitted earnings assertion for the Singapore and Kewaunee Labway India Pvt. Ltd. international subsidiaries. The Company has a deferred tax liability of $1,431,000 and $1,572,000 for the withholding tax related to Kewaunee Labway India Pvt. Ltd. as of January 31, 2025 and April 30, 2024, respectively.